Literature DB >> 16491166

Rho/Rho kinase as a potential target for the treatment of renal disease.

Shu Wakino1, Takeshi Kanda, Koichi Hayashi.   

Abstract

The small G-protein Rho and its downstream effector Rho kinase constitute important mediators not only of vascular contraction but also of actin cytoskeleton reorganization, cellular morphology, motility, adhesion and proliferation. The Rho/Rho kinase pathway plays an important role in the structure and function of various kidney cells including tubular epithelial cells, mesangial cells and podocytes. The Rho/Rho kinase pathway also regulates glomerular blood flow and glomerular filtration rate by modulating renal arteriolar contractility. Potent and specific inhibitors of Rho kinase have recently been developed and their therapeutic effects on a variety of renal injury models have been examined. In the rat models of hypertensive glomerulosclerosis, unilateral ureteral obstruction (for interstitial renal fibrosis) and ischemia/reperfusion acute renal failure, treatment with novel Rho kinase inhibitors attenuates the development of renal damage. Although human data connecting the activation of Rho/Rho kinase pathway and kidney disease are still lacking, these studies have provided compelling evidence for the renoprotective effects of Rho kinase inhibitors. (c) 2005 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16491166     DOI: 10.1358/dnp.2005.18.10.959578

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  9 in total

1.  The mitochondrial inner membrane GTPase, optic atrophy 1 (Opa1), restores mitochondrial morphology and promotes neuronal survival following excitotoxicity.

Authors:  Arezu Jahani-Asl; Karine Pilon-Larose; William Xu; Jason G MacLaurin; David S Park; Heidi M McBride; Ruth S Slack
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

Review 2.  Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD.

Authors:  Wenshan Lv; Fan Fan; Yangang Wang; Ezekiel Gonzalez-Fernandez; Chen Wang; Lili Yang; George W Booz; Richard J Roman
Journal:  Physiol Genomics       Date:  2017-11-10       Impact factor: 3.107

Review 3.  Actin dynamics at focal adhesions: a common endpoint and putative therapeutic target for proteinuric kidney diseases.

Authors:  Sanja Sever; Mario Schiffer
Journal:  Kidney Int       Date:  2018-04-17       Impact factor: 10.612

Review 4.  RhoA/Rho-kinase and vascular diseases: what is the link?

Authors:  Kenia Pedrosa Nunes; Christine S Rigsby; R Clinton Webb
Journal:  Cell Mol Life Sci       Date:  2010-07-29       Impact factor: 9.261

5.  Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKG-PPARγ axis.

Authors:  Jian Wang; Kai Yang; Lei Xu; Yi Zhang; Ning Lai; Hua Jiang; Yajie Zhang; Nanshan Zhong; Pixin Ran; Wenju Lu
Journal:  Am J Respir Cell Mol Biol       Date:  2013-08       Impact factor: 6.914

Review 6.  Fibrogenesis in kidney transplantation: potential targets for prevention and therapy.

Authors:  Arjang Djamali; Millie Samaniego
Journal:  Transplantation       Date:  2009-11-27       Impact factor: 4.939

Review 7.  Cyclic nucleotide signalling in kidney fibrosis.

Authors:  Elisabeth Schinner; Veronika Wetzl; Jens Schlossmann
Journal:  Int J Mol Sci       Date:  2015-01-22       Impact factor: 5.923

8.  Renal and vascular benefits of C-peptide: Molecular mechanisms of C-peptide action.

Authors:  Lina Nordquist; Fredrik Palm; Bradley T Andresen
Journal:  Biologics       Date:  2008-09

Review 9.  Biological pathways and potential targets for prevention and therapy of chronic allograft nephropathy.

Authors:  Badri Man Shrestha; John Haylor
Journal:  Biomed Res Int       Date:  2014-05-27       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.